Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NuCanaFRA:N040 30 EV-to-EBIT is 0.40 as of Aug. 16, 2026. GuruFocus rates FRA:N040 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 370 Biotechnology companies, NuCana ranks better than 82.16% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NuCana's Enterprise Value is €-10.72 Mil.
NuCana's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-26.55 Mil. Therefore, NuCana's EV-to-EBIT for today is 0.40.
The historical rank and industry rank for NuCana's EV-to-EBIT or its related term are showing as below:
FRA:N040'
s EV-to-EBIT Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.69
Current: 0.69
During the past 11 years, the highest EV-to-EBIT of NuCana was 0.69. The lowest was 0.00. And the median was 0.00.
FRA:N040's EV-to-EBIT is ranked better than 82.16% of 370
companies
in the Biotechnology industry
Industry Median: 16.245
vs FRA:N040: 0.69
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NuCana's Enterprise Value for the quarter that ended in Mar. 2026 was €-10.73 Mil.
NuCana's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NuCana EV-to-EBIT Related Terms
NuCana EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for NuCana's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:N040 vs CURX, DRMA, CELZ: EV-to-EBIT Comparison
For the Biotechnology subindustry, NuCana's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NuCana EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NuCana's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NuCana's EV-to-EBIT falls into.
NuCana's current Enterprise Value is €-10.72 Mil.
NuCana's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NuCana (FRA:N040) has a EV-to-EBIT of 0.40 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NuCana and its competitors. According to the industry distribution chart, NuCana ranks #66 out of 370 companies in the Biotechnology industry, placing it in the top 17.8%.
Is NuCana's EV-to-EBIT too high?
NuCana's current EV-to-EBIT is 0.40. The Biotechnology industry median EV-to-EBIT is 16.25. NuCana's value of 0.40 is 97.5% below this industry median. Based on the distribution chart, NuCana ranks #66 out of 370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NuCana has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does NuCana's EV-to-EBIT compare to CURX and DRMA?
According to the Biotechnology industry distribution chart, NuCana ranks #66 out of 370 companies for EV-to-EBIT. This places NuCana in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.25. NuCana's value of 0.40 is 97.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.25, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NuCana's current EV-to-EBIT of 0.40 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NuCana and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NuCana's current EV-to-EBIT is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NuCana stock overvalued right now?
NuCana (FRA:N040) has a current EV-to-EBIT of 0.40. The current EV-to-EBIT is 0.40 and 97.5% below the Biotechnology industry median of 16.25. NuCana's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For NuCana (FRA:N040), the current EV-to-EBIT is 0.40 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
30GF Score
Get the complete analysis for FRA:N040
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N040 has been successfully added to your 
